title: Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei.
abstract: The behavioral effects of peripherally administered interleukin-1beta (IL-1beta) are mediated by the production of cytokines and other proinflammatory mediators at the level of the blood-brain interface and by activation of neural pathway. To assess whether this action is mediated by NFkappaB activation, rats were injected into the lateral ventricle of the brain with a specific inhibitor of NFkappaB activation, the NEMO Binding Domain (NBD) peptide that has been shown previously to abolish completely IL-1beta-induced NFkappaB activation and Cox-2 synthesis in the brain microvasculature. NFkappaB pathway inactivation significantly blocked the behavioral effects of intraperitoneally administered IL-1beta in the form of social withdrawal and decreased food intake, and dramatically reduced IL-1beta-induced c-Fos expression in various brain regions as paraventricular nucleus, supraoptic nucleus, and lateral part of the central amygdala. These findings strongly support the hypothesis that IL-1beta-induced NFkappaB activation at the blood-brain interface is a crucial step in the transmission of immune signals from the periphery to the brain that underlies further events responsible of sickness behavior.
authors.affiliation: UMR INRA I 244-CNRS-Université Victor Segalen Bordeaux II, Institut François Magendie, rue Léo Saignat Bordeaux, Cedex, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Nadjar
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Bluthé
authors.forename: Michael J
authors.initials: MJ
authors.lastname: May
authors.forename: Robert
authors.initials: R
authors.lastname: Dantzer
authors.forename: Patricia
authors.initials: P
authors.lastname: Parnet
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects* / Q000378:metabolism; D004347:Drug Interactions; D004435:Eating / Q000187:drug effects; D004790:Enzyme Induction; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects* / Q000502:physiology; D046353:Immobility Response, Tonic / Q000187:drug effects; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D012919:Social Behavior; D013997:Time Factors
chemical_list: D004791:Enzyme Inhibitors; D007375:Interleukin-1; D016328:NF-kappa B; D016760:Proto-Oncogene Proteins c-fos